{'fraction_non_alphanumeric': 0.025604551920341393, 'fraction_numerical': 0.0, 'mean_word_length': 5.518518518518518, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
How to improve the risk‐benefit ratio of cyclosporin therapy for psoriasis

CsA therapy for psoriasis is hampered by side‐effects. Topical CsA therapy is not effective. Therefore improvement of the risk‐benefit ratio must be achieved by improvement of dose‐regimens, combination therapy of CsA with another therapy for psoriasis or combination therapy of CsA with a therapy that may influence the pathogenesis of the most serious side‐effect(s) of CsA. It seems that only therapies that influence the pathogenesis of CsA‐ induced acute renal‐impairment, like oral fish oil or perhaps thromboxane synthesis inhibitors, may be beneficial. However, further studies are warranted to validate these findings.